OpenAI Acquires Biotech Software Startup Orchestra Bio
US artificial intelligence company OpenAI on Tuesday acquired Orchestra Bio, a four-year-old startup that builds AI agents for biotech firms. The financial terms were not disclosed.
OpenAI, the US artificial intelligence company, announced on Tuesday, October 20, that it has acquired Orchestra Bio, a four-year-old biotech software startup. The deal strengthens OpenAI's life sciences business, where it offers specialised AI tools to researchers and pharmaceutical companies.
The terms of the transaction were not disclosed. According to earlier reports, Orchestra Bio had raised roughly $20 million as of 2025 from investors including Andreessen Horowitz, Atria and 8VC.
What Orchestra Bio does
The startup builds AI agents that help biotech companies handle the day-to-day work of drug discovery operations, from tracking finances to sorting out scheduling problems in clinical trials.
How OpenAI will use it
OpenAI says Orchestra's team and technology will join its work on Rosalind, its AI model for life sciences research, and on the related Rosalind Workbench, a tool that helps researchers plan experiments and analyse results. According to OpenAI, Rosalind already counts Moderna and Novo Nordisk among its customers.
The acquisition reflects a trend in which the largest AI labs, including OpenAI and Anthropic, are developing more and more software for major industries such as pharmaceuticals. Startups are widely concerned that the labs could launch new features at any moment and become competitors. In Orchestra's case, the company is being absorbed into OpenAI rather than pushed out of the market.
